Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 5, 2010, Pages 466-472

  Pabla, Dimple ^a   Akhlaghi, Fatemeh ^a   Zia, Hossein ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Absorption enhancer; Capric acid; Intestinal absorption; Lauric acid; Levothyroxine; MDCK cells; Oleic acid; Paracellular transport; Permeability; Tight junction

Indexed keywords

DECANOIC ACID; FATTY ACID DERIVATIVE; LACTATE DEHYDROGENASE; LAURIC ACID; LEVOTHYROXINE SODIUM; LUCIFER YELLOW; OLEIC ACID; PROPIDIUM IODIDE; FATTY ACID; THYROXINE;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL STRAIN; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG TRANSPORT; ELECTRIC RESISTANCE; ENZYME RELEASE; EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; TIGHT JUNCTION; ANIMAL; CELL LINE; CHEMISTRY; DOG; DRUG EFFECTS; HYPOTHYROIDISM; INTESTINE ABSORPTION; METABOLISM; PERMEABILITY; PHARMACEUTICS; PHYSICAL CHEMISTRY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; DOGS; EPITHELIAL CELLS; FATTY ACIDS; HYPOTHYROIDISM; INTESTINAL ABSORPTION; PERMEABILITY; PHYSICOCHEMICAL PHENOMENA; TECHNOLOGY, PHARMACEUTICAL; THYROXINE;

EID: 77953913991     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.05.002     Document Type: Article

References (39)

1. Anderberg E.K., Lindmark T., Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 1993, 10:857-864.
2. Artursson P., Karlsson J., Ocklind G., Schipper N. Studying transport processes in absorptive epithelia. Epithelial Cell Culture. A Practical Approach. 1996, 118-119. Oxford University Press, Inc., New York. A.J. Shaw (Ed.).
3. Benvenga S., Bartolone L., Squadrito S., Lo Giudice F., Trimarchi F. Delayed intestinal absorption of levothyroxine. Thyroid 1995, 5:249-253.
4. Bohets H., Annaert P., Mannens G., Van Beijsterveldt L., Anciaux K., Verboven P., Meuldermans W., Lavrijsen K. Strategies for absorption screening in drug discovery and development. Curr. Top. Med. Chem. 2001, 1:367-383.
5. Carr D., McLeod D.T., Parry G., Thornes H.M. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin. Endocrinol. (Oxf.) 1988, 28:325-333.
6. Cho M.J., Adson A., Kezdy F.J. Transepithelial transport of aliphatic carboxylic acids studied in Madin Darby canine kidney (MDCK) cell monolayers. Pharm. Res. 1990, 7:325-331.
7. Cho M.J., Thompson D.P., Cramer C.T., Vidmar T.J., Scieszka J.F. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm. Res. 1989, 6:71-77.
8. Constantinides P.P., Welzel G., Ellens H., Smith P.L., Sturgis S., Yiv S.H., Owen A.B. Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharm. Res. 1996, 13:210-215.
9. DrugTopics Top 200 Brand Drugs by Unit in 2007 2007, (date accessed 23.02.07). http://www.drugtopics.com/.
10. FDA Prescription drug products; levothyroxine sodium. Federal Register 1997, 62:43535.
11. Hays M.T. Localization of human thyroxine absorption. Thyroid 1991, 1:241-248.
12. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001, 1:385-401.
13. Hidalgo I.J., Grass G.M., Hillgren K.M., Borchardt R.T. A new side-by-side diffusion cell for studying transport across epithelial cell monolayers. In Vitro Cell. Dev. Biol. 1992, 28A:578-580.
14. Higaki K., Yata T., Sone M., Ogawara K., Kimura T. Estimation of absorption enhancement by medium-chain fatty acids in rat large intestine. Res. Commun. Mol. Pathol. Pharmacol. 2001, 109:231-240.
15. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 1999, 88:28-33.
16. Kamm W., Jonczyk A., Jung T., Luckenbach G., Raddatz P., Kissel T. Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2). Eur. J. Pharm. Sci. 2000, 10:205-214.
17. Kim D.C., Burton P.S., Borchardt R.T. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm. Res. 1993, 10:1710-1714.
18. Klein I., Danzi S. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Thyroid 2003, 13:1127-1132.
19. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001, 344:501-509.
20. Larhed A.W., Artursson P., Grasjo J., Bjork E. Diffusion of drugs in native and purified gastrointestinal mucus. J. Pharm. Sci. 1997, 86:660-665.
21. Lindenberg M., Kopp S., Dressman J.B. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 2004, 58:265-278.
22. Lindmark T., Kimura Y., Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 1998, 284:362-369.
23. Lindmark T., Nikkila T., Artursson P. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 1995, 275:958-964.
24. Lindmark T., Soderholm J.D., Olaison G., Alvan G., Ocklind G., Artursson P. Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm. Res. 1997, 14:930-935.
25. Murakami M., Takada K., Fujii T., Muranishi S. Intestinal absorption enhanced by unsaturated fatty acids: inhibitory effect of sulfhydryl modifiers. Biochim. Biophys. Acta 1988, 939:238-246.
26. Nishimura K., Nozaki Y., Yoshimi A., Nakamura S., Kitagawa M., Kakeya N., Kitao K. Studies on the promoting effects of carboxylic acid derivatives on the rectal absorption of beta-lactam antibiotics in rats. Chem. Pharm. Bull. (Tokyo) 1985, 33:282-291.
27. Ogiso T., Iwaki M., Kashitani Y., Yamashita K. Enhancement by fatty acids of the rectal absorption of propranolol: in vitro evaluation in the rat. J. Pharmacobiodyn. 1991, 14:385-391.
28. Olveira G., Almaraz M.C., Soriguer F., Garriga M.J., Gonzalez-Romero S., Tinahones F., Ruiz de Adana M.S. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 1997, 46:707-711.
29. Pabla D., Akhlaghi F., Ahmed A., Zia H. Development and validation of an inductively coupled plasma mass spectrometry method for quantification of levothyroxine in dissolution studies. Rapid Commun. Mass Spectrom. 2008, 22:993-996.
30. Ranaldi G., Islam K., Sambuy Y. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Agents Chemother. 1992, 36:1374-1381.
31. Ranaldi G., Seneci P., Guba W., Islam K., Sambuy Y. Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines. Antimicrob. Agents Chemother. 1996, 40:652-658.
32. Shroff A.P., Jones J.K. Standards for levothyroxine preparations. JAMA 1980, 244:658-659.
33. Singer P.A., Cooper D.S., Levy E.G., Ladenson P.W., Braverman L.E., Daniels G., Greenspan F.S., McDougall I.R., Nikolai T.F. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995, 273:808-812.
34. Stone E., Leiter L.A., Lambert J.R., Silverberg J.D., Jeejeebhoy K.N., Burrow G.N. l-Thyroxine absorption in patients with short bowel. J. Clin. Endocrinol. Metab. 1984, 59:139-141.
35. Swenson E.S., Curatolo W.J. Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 1992, 8:39-92.
36. Takatsuka S., Kitazawa T., Morita T., Horikiri Y., Yoshino H. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur. J. Pharm. Biopharm. 2006, 62:52-58.
37. Tomita M., Hayashi M., Awazu S. Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells. J. Pharmacol. Exp. Ther. 1995, 272:739-743.
38. Wartofsky L. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin. Pharmacother. 2002, 3:727-732.
39. Werner U., Kissel T., Reers M. Effects of permeation enhancers on the transport of a peptidomimetic thrombin inhibitor (CRC 220) in a human intestinal cell line (Caco-2). Pharm. Res. 1996, 13:1219-1227.